Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
20 Maio 2024 - 11:49AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of May 2024
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the
'Company')
Transaction notification
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Sally Jackson
|
b)
|
Position/status
|
SVP, Global Communications & CEO Office
|
c)
|
Initial
notification/ amendment
|
Initial Notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GSK plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary Shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
b)
|
Nature of
the transaction
|
The sale of 1,120 Ordinary Shares to facilitate a transfer into an
ISA
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£17.88
|
1,120
|
|
|
|
|
|
d)
|
Aggregated information
|
N/A (single transaction)
|
Aggregated volume Price
|
|
e)
|
Date
of the transaction
|
2024-05-16
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Sally Jackson
|
b)
|
Position/status
|
SVP, Global Communications & CEO Office
|
c)
|
Initial
notification/ amendment
|
Initial Notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GSK plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary Shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
b)
|
Nature of
the transaction
|
The purchase of 1,112 Ordinary Shares into an ISA
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£17.8700
|
1,112
|
|
|
|
|
|
d)
|
Aggregated information
|
N/A (single transaction)
|
Aggregated volume Price
|
|
e)
|
Date
of the transaction
|
2024-05-16
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Dylan Jackson
|
b)
|
Position/status
|
PCA of Sally Jackson (SVP, Global Communications & CEO
Office)
|
c)
|
Initial
notification/ amendment
|
Initial Notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GSK plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary Shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
b)
|
Nature of
the transaction
|
The sale of 1,120 Ordinary Shares to facilitate a transfer into an
ISA
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£17.87
|
1,120
|
|
|
|
|
|
d)
|
Aggregated information
|
N/A (single transaction)
|
Aggregated volume Price
|
|
e)
|
Date
of the transaction
|
2024-05-16
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Dylan Jackson
|
b)
|
Position/status
|
PCA of Sally Jackson (SVP, Global Communications & CEO
Office)
|
c)
|
Initial
notification/ amendment
|
Initial Notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GSK plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
Ordinary Shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
b)
|
Nature of
the transaction
|
The purchase of 1,112 Ordinary Shares into an ISA
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£17.8740
|
1,112
|
|
|
|
|
|
d)
|
Aggregated information
|
N/A (single transaction)
|
Aggregated volume Price
|
|
e)
|
Date
of the transaction
|
2024-05-16
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Dr Hal Barron
|
b)
|
Position/status
|
Non-Executive Director
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GSK plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W2044
|
b)
|
Nature
of the transaction
|
Acquisition of ADSs within Dr Barron's GSK 401(k) plan account
following the reinvestment of dividends
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$44.8800
|
61
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
Aggregated
volume Price
|
|
e)
|
Date
of the transaction
|
2024-05-16
|
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Dr Hal Barron
|
b)
|
Position/status
|
Non-Executive Director
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GSK plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W2044
|
b)
|
Nature
of the transaction
|
Acquisition of notional ADSs within Dr Barron's GSK Executive
Supplemental Savings Plan account following the reinvestment of
dividends
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$44.8800
|
2,432.6749
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
Aggregated
volume Price
|
|
e)
|
Date
of the transaction
|
2024-05-16
|
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
James Ford
|
b)
|
Position/status
|
SVP and Group General Counsel, Legal and Compliance
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GSK plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W2044
|
b)
|
Nature
of the transaction
|
Acquisition of notional ADSs within Mr Ford's GSK Executive
Supplemental Savings Plan account following the reinvestment of
dividends
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$44.8800
|
45.2660
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
Aggregated
volume Price
|
|
e)
|
Date
of the transaction
|
2024-05-16
|
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GSK plc
|
|
(Registrant)
|
|
|
Date: May
20, 2024
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GSK plc
|
GSK (NYSE:GSK)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
GSK (NYSE:GSK)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024